<DOC>
	<DOCNO>NCT02012556</DOCNO>
	<brief_summary>The primary objective study determine PK ( tesamorelin ) PD ( IGF-1 ) profile tesamorelin single 2 mg subcutaneous administration repeat administration daily 14 consecutive day . Secondary objective include evaluation safety tolerability tesamorelin follow multiple subcutaneous injection .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamic Study TH9507 , Growth Hormone-Releasing Factor Analog , HIV Positive Patients</brief_title>
	<detailed_description />
	<mesh_term>Growth Hormone-Releasing Hormone</mesh_term>
	<criteria>Main Male female , smoker nonsmoker , ≥18 ≤65 year age . HIVpositive CD4 cell count &gt; 100 cells/mm3 viral load &lt; 10 000 copies/mL . On stable antiretroviral therapy ( ART ) regimen least 8 week prior first study drug administration . Body mass index ( BMI ) ≥ 20.0 kg/m2 . Main Opportunistic infection HIVrelated disease within 3 month prior study drug administration . History malignancy organ tissue ( exception basal cell carcinoma skin , situ carcinoma cervix stable Kaposi require treatment past 6 month ) . For male subject , suspicion prostate cancer . For female subject , history breast cancer strong family history ( first degree relative ) breast cancer . Known hypopituitarism , history pituitary tumor/surgery , head irradiation severe head trauma affect somatotropic axis . Use experimental market GH GRF/GHRH product , GH secretagogues , IGF1 , insulinlike growth factor bind protein3 ( IGFBP3 ) within 6 month prior study drug administration throughout study . Positive pregnancy test screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>